Mood stabilizer-regulated miRNAs in neuropsychiatric and neurodegenerative diseases: Identifying associations and functions

American Journal of Translational Research

Volumn 5, Issue 4, 2013, Pages 450-464

  Hunsberger, Joshua G ^a   Fessler, Emily B ^a   Chibane, Fairouz L ^a   Leng, Yan ^a   Maric, Dragan ^c   Elkahloun, Abdel G ^b   Chuang, De Maw ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Glutamate excitotoxicity; Lithium; microRNA; Mood stabilizers; Neuroprotection; Valproic acid

Indexed keywords

LITHIUM; MICRORNA; MOOD STABILIZER; VALPROIC ACID;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO GENE TRANSFER; MENTAL DISEASE; MICROARRAY ANALYSIS; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION;

RATTUS;

EID: 84878323018     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
2. Filipowicz W, Bhattacharyya SN and Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9: 102-114.
3. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B and Rigoutsos I. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006; 126: 1203-1217.
4. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W and Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-739.
5. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M and Greenberg ME. A brain-specific microRNA regulates dendritic spine development. Nature 2006; 439: 283-289.
6. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355.
7. Lehmann SM, Kruger C, Park B, Derkow K, Rosenberger K, Baumgart J, Trimbuch T, Eom G, Hinz M, Kaul D, Habbel P, Kalin R, Franzoni E, Rybak A, Nguyen D, Veh R, Ninnemann O, Peters O, Nitsch R, Heppner FL, Golenbock D, Schott E, Ploegh HL, Wulczyn FG and Lehnardt S. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci 2012; 15: 827-835.
8. Wang G, van der Walt JM, Mayhew G, Li YJ, Zuchner S, Scott WK, Martin ER and Vance JM. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 2008; 82: 283-289.
9. Kim AH, Reimers M, Maher B, Williamson V, McMichael O, McClay JL, van den Oord EJ, Riley BP, Kendler KS and Vladimirov VI. MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr Res 2010; 124: 183-191.
10. Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, Li M, Wang G and Liu Y. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 2009; 37: D98-104.
11. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y, Damschroder-Williams P, Du J, Chen G and Manji HK. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 2009; 34: 1395-1405.
12. Hashimoto R, Hough C, Nakazawa T, Yamamoto T and Chuang DM. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002; 80: 589-597.
13. Nonaka S, Hough CJ and Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 1998; 95: 2642-2647.
14. Kanai H, Sawa A, Chen RW, Leeds P and Chuang DM. Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogenomics J 2004; 4: 336-344.
15. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH and Manji HK. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999; 72: 879-882.
16. Chen RW and Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999; 274: 6039-6042.
17. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P and Chuang DM. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 2008; 28: 2576-2588.
18. Feng HL, Leng Y, Ma CH, Zhang J, Ren M and Chuang DM. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 2008; 155: 567-572.
19. Chiu CT, Liu G, Leeds P and Chuang DM. Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology 2011; 36: 2406-2421.
20. Leng Y, Marinova Z, Reis-Fernandes MA, Nau H and Chuang DM. Potent neuroprotective effects of novel structural derivatives of valproic acid: potential roles of HDAC inhibition and HSP70 induction. Neurosci Lett 2010; 476: 127-132.
21. Leng Y and Chuang DM. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 2006; 26: 7502-7512.
22. Hillion JA, Takahashi K, Maric D, Ruetzler C, Barker JL and Hallenbeck JM. Development of an ischemic tolerance model in a PC12 cell line. J Cereb Blood Flow Metab 2005; 25: 154-162.
23. Hunsberger JG, Fessler EB, Wang Z, Elkahloun AG and Chuang DM. Post-insult valproic acid-regulated microRNAs: potential targets for cerebral ischemia. Am J Transl Res 2012; 4: 316-332.
24. Dweep H, Sticht C, Pandey P and Gretz N. miRWalk--database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011; 44: 839-847.
25. Papadopoulos GL, Alexiou P, Maragkakis M, Reczko M and Hatzigeorgiou AG. DIANA-mirPath: Integrating human and mouse microRNAs in pathways. Bioinformatics 2009; 25: 1991-1993.
26. Sun ZW, Zhang L, Zhu SJ, Chen WC and Mei B. Excitotoxicity effects of glutamate on human neuroblastoma SH-SY5Y cells via oxidative damage. Neurosci Bull 2010; 26: 8-16.
27. Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X, Huang L, Liu Y, Zhang L and Qin C. miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull 2009; 80: 268-273.
28. Hu K, Xie YY, Zhang C, Ouyang DS, Long HY, Sun DN, Long LL, Feng L, Li Y and Xiao B. MicroRNA expression profile of the hippocampus in a rat model of temporal lobe epilepsy and miR-34a-targeted neuroprotection against hippocampal neurone cell apoptosis post-status epilepticus. BMC Neurosci 2012; 13: 115.
29. Khanna A, Muthusamy S, Liang R, Sarojini H and Wang E. Gain of survival signaling by down-regulation of three key miRNAs in brain of calorie-restricted mice. Aging (Albany NY) 2011; 3: 223-236.
30. Delay C, Calon F, Mathews P and Hebert SS. Alzheimer-specific variants in the 3'UTR of Amyloid precursor protein affect microRNA function. Mol Neurodegener 2011; 6: 70.
31. Mallick B and Ghosh Z. A complex crosstalk between polymorphic microRNA target sites and AD prognosis. RNA Biol 2011; 8: 665-673.
32. Liu G, Friggeri A, Yang Y, Park YJ, Tsuruta Y and Abraham E. miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proc Natl Acad Sci U S A 2009; 106: 15819-15824.
33. Lee YJ, Johnson KR and Hallenbeck JM. Global protein conjugation by ubiquitin-like-modifiers during ischemic stress is regulated by microRNAs and confers robust tolerance to ischemia. PLoS One 2012; 7: e47787.
34. Lee ST, Chu K, Jung KH, Yoon HJ, Jeon D, Kang KM, Park KH, Bae EK, Kim M, Lee SK and Roh JK. MicroRNAs induced during ischemic preconditioning. Stroke 2010; 41: 1646-1651.
35. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, Weinstock DM, Gorospe M, Harris AL, Helleday T and Chowdhury D. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011; 41: 210-220.
36. Zhou S, Shen D, Wang Y, Gong L, Tang X, Yu B, Gu X and Ding F. microRNA-222 targeting PTEN promotes neurite outgrowth from adult dorsal root ganglion neurons following sciatic nerve transection. PLoS One 2012; 7: e44768.
37. Kan AA, van Erp S, Derijck AA, de Wit M, Hessel EV, O'Duibhir E, de Jager W, Van Rijen PC, Gosselaar PH, de Graan PN and Pasterkamp RJ. Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune response. Cell Mol Life Sci 2012; 69: 3127-3145.
38. Mellios N, Huang HS, Grigorenko A, Rogaev E and Akbarian S. A set of differentially expressed miRNAs, including miR-30a-5p, act as post-transcriptional inhibitors of BDNF in prefrontal cortex. Hum Mol Genet 2008; 17: 3030-3042.
39. Brandenburger T, Castoldi M, Brendel M, Grievink H, Schlosser L, Werdehausen R, Bauer I and Hermanns H. Expression of spinal cord microRNAs in a rat model of chronic neuropathic pain. Neurosci Lett 2012; 506: 281-286.
40. Tsai LK, Leng Y, Wang Z, Leeds P and Chuang DM. The mood stabilizers valproic acid and lithium enhance mesenchymal stem cell migration via distinct mechanisms. Neuropsychopharmacology 2010; 35: 2225-2237.
41. Tsai LK, Wang Z, Munasinghe J, Leng Y, Leeds P and Chuang DM. Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model. Stroke 2011; 42: 2932-2939.
42. Dobolyi A, Vincze C, Pal G and Lovas G. The neuroprotective functions of transforming growth factor Beta proteins. Int J Mol Sci 2012; 13: 8219-8258.
43. Santarelli DM, Beveridge NJ, Tooney PA and Cairns MJ. Upregulation of dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann area 46 in schizophrenia. Biol Psychiatry 2011; 69: 180-187.
44. Boche D, Cunningham C, Gauldie J and Perry VH. Transforming growth factor-beta 1-mediated neuroprotection against excitotoxic injury in vivo. J Cereb Blood Flow Metab 2003; 23: 1174-1182.
45. Liang MH, Wendland JR and Chuang DM. Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling. Mol Cell Neurosci 2008; 37: 440-453.
46. Sarachana T, Zhou R, Chen G, Manji HK and Hu VW. Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med 2010; 2: 23.
47. Perkins DO, Jeffries CD, Jarskog LF, Thomson JM, Woods K, Newman MA, Parker JS, Jin J and Hammond SM. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 2007; 8: R27.
48. Marti E, Pantano L, Banez-Coronel M, Llorens F, Minones-Moyano E, Porta S, Sumoy L, Ferrer I and Estivill X. A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing. Nucleic Acids Res 2010; 38: 7219-7235.
49. Martins M, Rosa A, Guedes LC, Fonseca BV, Gotovac K, Violante S, Mestre T, Coelho M, Rosa MM, Martin ER, Vance JM, Outeiro TF, Wang L, Borovecki F, Ferreira JJ and Oliveira SA. Convergence of miRNA expression profiling, alpha-synuclein interacton and GWAS in Parkinson's disease. PLoS One 2011; 6: e25443.
50. Geekiyanage H, Jicha GA, Nelson PT and Chan C. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. Exp Neurol 2012; 235: 491-496.
51. Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, Kauppinen S, Delacourte A and De Strooper B. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci U S A 2008; 105: 6415-6420.
52. Geekiyanage H and Chan C. MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid beta, novel targets in sporadic Alzheimer's disease. J Neurosci 2011; 31: 14820-14830.
53. Shioya M, Obayashi S, Tabunoki H, Arima K, Saito Y, Ishida T and Satoh J. Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol Appl Neurobiol 2010; 36: 320-330.
54. Moreau MP, Bruse SE, David-Rus R, Buyske S and Brzustowicz LM. Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder. Biol Psychiatry 2011; 69: 188-193.
55. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD and Richards CA. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 2008; 14: 27-41.
56. Wang WX, Huang Q, Hu Y, Stromberg AJ and Nelson PT. Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta Neuropathol 2011; 121: 193-205.
57. Sinha M, Ghose J, Das E and Bhattarcharyya NP. Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP. Biochem Biophys Res Commun 2010; 396: 742-747.
58. Lai CY, Yu SL, Hsieh MH, Chen CH, Chen HY, Wen CC, Huang YH, Hsiao PC, Hsiao CK, Liu CM, Yang PC, Hwu HG and Chen WJ. MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One 2011; 6: e21635.
59. Beveridge NJ, Gardiner E, Carroll AP, Tooney PA and Cairns MJ. Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 2010; 15: 1176-1189.
60. Ghahramani Seno MM, Hu P, Gwadry FG, Pinto D, Marshall CR, Casallo G and Scherer SW. Gene and miRNA expression profiles in autism spectrum disorders. Brain Res 2011; 1380: 85-97.
61. Smalheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G and Dwivedi Y. MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS One 2012; 7: e33201.
62. Abu-Elneel K, Liu T, Gazzaniga FS, Nishimura Y, Wall DP, Geschwind DH, Lao K and Kosik KS. Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics 2008; 9: 153-161.
63. Ghose J, Sinha M, Das E, Jana NR and Bhattacharyya NP. Regulation of miR-146a by RelA/NFkB and p53 in STHdh(Q111)/Hdh(Q111) cells, a cell model of Huntington's disease. PLoS One 2011; 6: e23837.
64. Beveridge NJ, Tooney PA, Carroll AP, Gardiner E, Bowden N, Scott RJ, Tran N, Dedova I and Cairns MJ. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet 2008; 17: 1156-1168.
65. Schipper HM, Maes OC, Chertkow HM and Wang E. MicroRNA expression in Alzheimer blood mononuclear cells. Gene Regul Syst Bio 2007; 1: 263-274.
66. Saus E, Soria V, Escaramis G, Vivarelli F, Crespo JM, Kagerbauer B, Menchon JM, Urretavizcaya M, Gratacos M and Estivill X. Genetic variants and abnormal processing of pre-miR-182, a circadian clock modulator, in major depression patients with late insomnia. Hum Mol Genet 2010; 19: 4017-4025.
67. Gaughwin PM, Ciesla M, Lahiri N, Tabrizi SJ, Brundin P and Bjorkqvist M. Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. Hum Mol Genet 2011; 20: 2225-2237.
68. Minones-Moyano E, Porta S, Escaramis G, Rabionet R, Iraola S, Kagerbauer B, Espinosa-Parrilla Y, Ferrer I, Estivill X and Marti E. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 2011; 20: 3067-3078.